Bristol Myers Loses 20.7% in 3 Months: Buy, Sell or Hold the Stock?
BMY slides 20.7% in 3 months despite strong Q1 and raised outlook, as generic pressure and pipeline setbacks weigh on investor sentiment.
Bristol-Myers Squibb Company (BMY) Bernstein 41st Annual Strategic Decisions Conference (Transcript)
Bristol-Myers Squibb Company (NYSE:BMY ) Bernstein 41st Annual Strategic Decisions Conference May 28, 2025 3:30 PM ET Company Participants Chris Boerner - Chief Executive Officer & Chairman Confere...
Bristol-Myers Squibb's Painful Pullback Has Triggered Richer Dividend Story - Upgrade To Buy
Bristol Myers Squibb's much needed correction has brought the stock back to earth, nearer to its 1Y means while triggering the expanded forward dividend yields. Its dividend investment thesis appea...
Bristol-Myers Squibb: This Undervalued Dog Needs An Option Collar
Bristol-Myers Squibb Company appears deeply undervalued, despite business headwinds and revenue declines from legacy products facing generic competition. The market is already pricing in revenue an...
Bristol-Myers: Among The Cheapest Pharma Names, Now Yielding Above 5%
I reiterate my buy rating on Bristol-Myers, seeing significant undervaluation despite persistent weak technicals and sector underperformance. BMY's strong earnings beats, high free cash flow yield,...
Bristol-Myers Squibb At ASCO 2025: A Resilient Play Amid Market Turbulence
Despite socio-economic challenges and pressure from the generic versions of Revlimid and Abraxane, Bristol-Myers Squibb Company's financial position continues to improve. It raised its 2025 diluted...
When It Rains Gold, Put Out The Bucket: 2 Wonderful Income Bargains
Focus on high-quality, dividend-paying stocks with temporary setbacks, offering both value and income for patient investors. Bristol-Myers Squibb is deeply undervalued, carries a 5.3% yield, strong...
First-Quarter GDP Halfway to Recession: Move to These Safe High-Yield Dividend Stocks Now
The first report for U.S. gross domestic product (GDP) came in at −0.3% as the economy contracted for the first time in three years.
This High-Yield Pharma Stock Looks Like an Incredible Bargain
When markets get choppy, smart investors often seek refuge in pharmaceutical stocks. These companies typically offer consistent cash flows, essential products, and solid dividends regardless of eco...
BMY Beats on Q1 Earnings and Sales, Raises 2025 Outlook
BMY beats on both earnings and sales in the first quarter of 2025. The company raises its guidance for the full year.
Bristol Myers Squibb Posts Better-than-Expected Earnings, Raises Full-Year Guidance
Bristol Myers sees revenue decline in its legacy drug portfolio due to competition and Medicare headwinds.
U.S. Food and Drug Administration Updates CAMZYOS® (mavacamten) Label to Reduce Echocardiography Monitoring Requirements and Contraindications
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CAMZYOS--U.S. Food and Drug Administration Updates CAMZYOS® (mavacamten) Label to Reduce Echocardiography Monitoring Requirements and Contraindications.
Should You Buy, Hold, or Sell BMY Stock Ahead of Q1 Earnings?
Bristol Myers is looking to turn its business around, banking on the strong uptake of new drugs. However, the 2025 outlook is not bright and we recommend investors to wait and watch for now.
BMY Down on Heart Drug Camzyos Failure in Late-Stage Study
Bristol Myers phase III study evaluating Camzyos for the treatment of adult patients with non-obstructive hypertrophic cardiomyopathy fails to meet its dual-primary endpoints.
Bristol-Myers Squibb Stock: A Strong Buy Amid Oncology Success
Bristol-Myers Squibb has shown exceptional success in addressing challenges directly related to the introduction of generic versions of Revlimid and Sprycel. So, the gem in its oncology franchise i...
Related Companies